Does IMATINIB Cause Focal segmental glomerulosclerosis? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Focal segmental glomerulosclerosis have been filed in association with IMATINIB (Imatinib). This represents 0.0% of all adverse event reports for IMATINIB.
11
Reports of Focal segmental glomerulosclerosis with IMATINIB
0.0%
of all IMATINIB reports
0
Deaths
7
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From IMATINIB?
Of the 11 reports, 7 (63.6%) required hospitalization.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does IMATINIB Cause?
Death (9,708)
Drug ineffective (2,628)
Nausea (2,379)
Diarrhoea (2,203)
Fatigue (1,810)
Malignant neoplasm progression (1,716)
Vomiting (1,599)
Malaise (1,361)
Drug intolerance (1,354)
Drug resistance (1,293)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which IMATINIB Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
IMATINIB vs IMBRUVICA
IMATINIB vs IMDEVIMAB
IMATINIB vs IMEGLIMIN
IMATINIB vs IMETELSTAT
IMATINIB vs IMIDAPRIL